Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 3 | 2006 | 88 | 0.170 |
Why?
|
| Antiviral Agents | 3 | 2015 | 313 | 0.150 |
Why?
|
| Liver Transplantation | 2 | 2015 | 207 | 0.150 |
Why?
|
| Liver Cirrhosis | 3 | 2006 | 164 | 0.130 |
Why?
|
| Simeprevir | 1 | 2015 | 6 | 0.120 |
Why?
|
| Sofosbuvir | 1 | 2015 | 18 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2015 | 140 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2015 | 143 | 0.110 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2006 | 11 | 0.080 |
Why?
|
| Stomach Diseases | 1 | 2006 | 10 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2006 | 14 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2002 | 18 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2002 | 33 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 66 | 0.050 |
Why?
|
| Iron | 1 | 2002 | 136 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 135 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 621 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 1613 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 850 | 0.030 |
Why?
|
| Platelet Count | 2 | 2006 | 25 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2354 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 45 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 223 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3090 | 0.030 |
Why?
|
| Mutation | 1 | 2002 | 2462 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 452 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 608 | 0.030 |
Why?
|
| Prevalence | 2 | 2006 | 1262 | 0.020 |
Why?
|
| Middle Aged | 4 | 2015 | 16452 | 0.020 |
Why?
|
| Liver | 2 | 2006 | 798 | 0.020 |
Why?
|
| Disease Progression | 2 | 2006 | 1127 | 0.020 |
Why?
|
| Male | 4 | 2015 | 27952 | 0.020 |
Why?
|
| Time Factors | 2 | 2006 | 3629 | 0.020 |
Why?
|
| Female | 4 | 2015 | 30926 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 69 | 0.020 |
Why?
|
| Bilirubin | 1 | 2006 | 17 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2006 | 45 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 51 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 420 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2006 | 138 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 204 | 0.010 |
Why?
|
| Humans | 5 | 2015 | 59744 | 0.010 |
Why?
|
| Hemochromatosis Protein | 1 | 2002 | 4 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 393 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 155 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2002 | 99 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 162 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 186 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 90 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 150 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 354 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 499 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 827 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1315 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 804 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5011 | 0.010 |
Why?
|
| Massachusetts | 1 | 2002 | 2027 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 6156 | 0.010 |
Why?
|
| Adult | 1 | 2002 | 15771 | 0.000 |
Why?
|